FOLH1 and short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome: Recognizing this challenge, the AlphaBet trial [108] investigated the combination of Ra-223 and Lu-177 PSMA to target both bone and soft-tissue metastases.